![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, May 28, 2010 4:19:44 PM
HBRM news. Herborium Group, Inc. Focuses on a Lucrative Botanical Therapeutics Market
SADDLE BROOK, NJ, May 28, 2010 (MARKETWIRE via COMTEX) -- Herborium Group, Inc. (PINKSHEETS: HBRM) (www.herborium.com), a botanical therapeutics(R) company that develops, licenses and markets all natural, herbal medicinal products, has focused its efforts on developing aggressive routes of taping into $33 billion over the counter alternative medicine market in the USA and over a trillion USD global market for alternative and complementary medicine.
The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.
Herborium pipeline of botanical therapeutics in the sectors of dermatology (Acne -- global market is over 55 Billion USD and over 60 million Americans are diagnosed and affected yearly by different forms of acne -- www.acnease.com), women's and men's health, including BPH (benign prostate hyperplasia affects over half of male population at the age of 50+) and liver health, belong to the most growing category of CAM products (self care costs) that reached $22 Billion in the US last year with majority going to purchase of non-vitamin, and non-mineral products.
"With the conversion of such factors as health economics, directing consumers to spend money on prevention and on non ethical products (lower insurance coverage) and to pharmaceutical companies being forced to remove drugs from the market for safety reasons (La Roche and Accutane for acne or Vioxx for pain), Herborium is ideally positioned to take advantage of those emerging market opportunities," said Dr. Agnes P. Olszewski, President of Herborium Group. "During last four months we have focused our activities on preparing to penetrate new markets with our existing products including targeting of foreign markets. We have signed or are in final stage of negotiating new distribution agreements in the USA and abroad that will greatly increase our customer base. We expect that our bottom line will significantly benefit from those initiatives in 2010 and 2011," continues Dr. Olszewski.
"We are also planning to introduce new and complementary products. We are especially excited about expected product line extension in the field of dermatology with a product targeting acne," adds Dr. Olszewski
"While securing additional resources we plan to address needs of consumers and health providers that look for highly efficient, proven safe and effective all natural alternatives in treatment and prevention of number of health problems and concerns," concludes Dr. Olszewski
About Herborium Group, Inc. Herborium Group, Inc., a botanical therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the forms 10-Q.
Company Contact:
Dr. Agnes P. Olszewski
President & CEO
Tel: (201) 647.3757 (201) 647.3757
SOURCE: Herborium Group, Inc.
Copyright 2010 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Financial Services:Investment Services and Trading
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Trials
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Drugs
SADDLE BROOK, NJ, May 28, 2010 (MARKETWIRE via COMTEX) -- Herborium Group, Inc. (PINKSHEETS: HBRM) (www.herborium.com), a botanical therapeutics(R) company that develops, licenses and markets all natural, herbal medicinal products, has focused its efforts on developing aggressive routes of taping into $33 billion over the counter alternative medicine market in the USA and over a trillion USD global market for alternative and complementary medicine.
The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage.
Herborium pipeline of botanical therapeutics in the sectors of dermatology (Acne -- global market is over 55 Billion USD and over 60 million Americans are diagnosed and affected yearly by different forms of acne -- www.acnease.com), women's and men's health, including BPH (benign prostate hyperplasia affects over half of male population at the age of 50+) and liver health, belong to the most growing category of CAM products (self care costs) that reached $22 Billion in the US last year with majority going to purchase of non-vitamin, and non-mineral products.
"With the conversion of such factors as health economics, directing consumers to spend money on prevention and on non ethical products (lower insurance coverage) and to pharmaceutical companies being forced to remove drugs from the market for safety reasons (La Roche and Accutane for acne or Vioxx for pain), Herborium is ideally positioned to take advantage of those emerging market opportunities," said Dr. Agnes P. Olszewski, President of Herborium Group. "During last four months we have focused our activities on preparing to penetrate new markets with our existing products including targeting of foreign markets. We have signed or are in final stage of negotiating new distribution agreements in the USA and abroad that will greatly increase our customer base. We expect that our bottom line will significantly benefit from those initiatives in 2010 and 2011," continues Dr. Olszewski.
"We are also planning to introduce new and complementary products. We are especially excited about expected product line extension in the field of dermatology with a product targeting acne," adds Dr. Olszewski
"While securing additional resources we plan to address needs of consumers and health providers that look for highly efficient, proven safe and effective all natural alternatives in treatment and prevention of number of health problems and concerns," concludes Dr. Olszewski
About Herborium Group, Inc. Herborium Group, Inc., a botanical therapeutics(R) company, focuses on developing, licensing, and marketing proprietary, botanical based medicinal products to consumers and healthcare professionals. The Company business model focuses on emerging market opportunities spearheaded by the growth of a new market sector located between high-cost, high-risk, ethical pharmaceuticals and commoditized classic nutraceuticals (supplements). The Company uses clinical validation and a proactive regulatory strategy based on the FDA Guidance for Industry: Botanical Drug Products (FDA Guidance 2004) to establish and maintain a differential advantage. Herborium harvests its therapeutic candidates from Traditional Chinese Medicine and utilizes Western regulatory, clinical and marketing strategies to successfully introduce the products to the Western markets. The company secured a pipeline of botanical ingredients based products in the areas of dermatological needs, Prostate Health (BPH), Liver Diseases, Women's Health and selected sexual disorders resulting from cardiovascular disease, use of anti-depressants, surgical procedures, and other problems. Herborium Group sells its products in the United States, the United Kingdom, and continental Europe through a network of distributors, specialty retailers, and e-commerce.
Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the forms 10-Q.
Company Contact:
Dr. Agnes P. Olszewski
President & CEO
Tel: (201) 647.3757 (201) 647.3757
SOURCE: Herborium Group, Inc.
Copyright 2010 Marketwire, Inc., All rights reserved.
-0-
SUBJECT CODE: Financial Services:Investment Services and Trading
Pharmaceuticals and Biotech:Biotech
Pharmaceuticals and Biotech:Trials
Pharmaceuticals and Biotech:Equipment and Supplies
Pharmaceuticals and Biotech:Drugs
PLAY the CHART!
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.